NASDAQ
0.87USD
-0.00 (-0.11%)
We have scored 7 news catalysts on Phio Pharmaceuticals Corp. (PHIO) over the past 12 months. The biggest single-day move next to one of them came Feb 10, 2026, when PHIO closed +24.4%: “Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients”. Coverage across the window leans positive (average ticker sentiment +0.56). Most of the impact sits in short squeeze potential and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
10.1M
P/E
—
EPS
—
Beta
0.84
52W range
0.8127-4.19
Day range
0.85–0.88
Open
0.87
Prev close
0.87
Volume
33.6K
Avg volume
468.9K
Dividend
0.00
IPO
2012-05-10
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Phio Pharmaceuticals Corp. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for PHIO: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
